AI Analysis Validates Positive Results for MASH Liver Treatment Trial

A Phase 2 clinical trial for zabopegdutide (DD01), an investigational treatment for metabolic dysfunction-associated steatohepatitis (MASH), has shown positive outcomes. AI-powered histopathological analysis confirmed significant improvements in liver fibrosis and MASH resolution after 48 weeks. Patients also experienced weight loss and better glycemic control, reinforcing the drug's potential.